

# Highlights

#### FY2019.12 result

- Demand progressed according to the forecast (issued on Nov. 8, 2019) (1USD=JPY108)
- Net sales 173.1 billion yen, EBITDA 5.2 billion yen, Operating loss 4.3 billion yen,
   Ordinary loss 4.6 billion yen, Net loss 4.1 billion yen
- Devices: Demand for smartphones fell far below the initial projection.
- Industrial Materials: Demand decrease for Chinese market caused low operation of domestic production. Challenge for profit improvement continues at an overseas molding factory.
- Medical Technologies: Demand progressed steadily.
- Growth strategy for non-IT: 3 acquisitions were implemented utilizing the gain on sale of unused fixed assets (one acquisition: SPA concluded and before the completion of acquisition)

#### Forecast for FY2020.12

- IFRS applied (1USD=JPY105)
- Net sales 166.0 billion yen, Operating loss 2.0 billion yen, Loss before tax 2.7 billion yen, Net loss 3.5 billion yen
- Costs for Measures to Strengthen Profitability included
- Thorough cost reduction in H1 and turn positive in H2



### FY2019.12 Results

# Lower demand for smartphones on Devices impacted

the results (Millions of JPY)

	FY2018.12 (JanDec.) Results	FY2019.12 (JanDec.) Results	YoY
Net sales	207,404	173,189	-16.5%
Industrial Materials	47,124	46,463	-1.4%
Devices	123,541	94,706	-23.3%
Medial Technologies	22,351	24,068	+7.7%
Information and Communication	13,935	7,417	*-46.8%
Others	452	534	+18.1%
EBITDA	17,343	5,221	-69.9%
EBITDA margin	8.4%	3.0%	-5.4pt
Operating profit	8,080	-4,307	-
Operating profit margin	3.9%	-2.5%	-6.4pt
Ordinary profit	7,380	-4,696	-
Net profit	4,318	-4,131	<del>-</del>
Forex	¥109/\$	¥108/\$	



# FY2019.12 Q4 (Oct.-Dec.) Results

(Millions of JPY)


		FY2019.12 JanMar.(Q1) Results	FY2019.12 AprJun.(Q2) Results	FY2019.12 JulSep.(Q3) Results	FY2019.12 OctDec.(Q4) Results	QoQ
Net sales		34,964	38,136	52,309	47,780	-8.7%
	Industrial Materials	11,672	11,882	· · · · · · · · · · · · · · · · · · ·	11,344	-1.9%
	Devices	15,072	18,394	33,257	27,983	-15.9%
	Medical Technologies	6,145	6,140	5,922	5,861	-1.0%
	Information and Communication	1,977	1,624	1,462	2,354	+61.0%
	Others	95	96	105	238	+126.7%
EBITDA		-170	-910	3,837	2,464	-35.8%
EBITDA n	EBITDA margin		-2.4%	7.3%	5.2%	-2.1pt
Operating profit		-2,508	-3,321	1,457	65	-95.5%
Operating profit margin		-7.2%	-8.7%	2.8%	0.1%	-2.7pt
Ordinary profit		-2,746	-3,641	1,320	371	-71.9%
Net pr	Net profit		-4,311	5,444	-2,006	-
Forex		¥109/\$	¥110/\$	¥106/\$	¥107/\$	



## **Industrial Materials**

# Continued sluggish demand for Chinese market in Q4 (Mobility)


Net sales trend by application (by quarter)





# Devices Demand progressed as projected in Q4

Net sales trend by application (by quarter)






#### **EMPOWERING YOUR VISION**

# Medical Technologies

Demand progressed steadily and grown consistently for the full year



### Information and Communication

Net sales trend by application (by quarter) (Millions of JPY) ■ Others 8,000 ■ Publication printing Commercial printing Business restructuring January 7, 2019 6,000 3,974 3,873 4,000 3,121 2,967 2,354 1,977 1,624 2,000 1,462 0 Q1 Q2 Q3 Q2 Q3 Q4 Q1 Q4 FY2018.12 FY2019.12 nissha

# Forecast for FY2020.12



10

## Leverage Measures to Strengthen Profitability in 2020 H1, improve profitability in 2020 H2

2019 (Result) 2020 (Forecast) 2021 (Image) IT demand decrease (Millions of JPY) 80,000 IT IT IT IT. Non 40,000 Non Non -IT Non -IT -IT -IT H2: Profitability to be improved H1: Measures to Strengthen Profitability Temporary expense of 2.0 billion yen incurs. H1 H2 H1 H2 ■ Net Sales H1 H2 Net Sales (Image) Measures to Strengthen Operating Profit (in case of Measures to Strengthen Profitability) Profitability (Cost reduction Operating Profit (in case of no Measures for about 2.5 billion JPY)

to Strengthen Profitability)


# Build optimal business structure for decreasing demand through Measures to Strengthen Profitability

# Management policy for IT


Addressing to decreasing demand

Implement Measures to Strengthen
Profitability

- Reduce investment burden
- Turn labor costs into variable costs
- Enhancement of automatization and laborsaving
  - Automatic inspection with AT
  - RPA



Reduce fixed costs
About 0.9 billion JPY for half a year
About 1.9 billion JPY for a full year





### Recovery of profitability and re-growth of sales

#### Europe

 Market share extension for metallized paper (Sustainable Packaging Materials)

Sales offices: Germany, UK Molding bases: Germany

#### Japan

 Lower factory operation due to lower demand from China

Reduce fixed cost (about 500 million JPY)

Sales offices: Kyoto Molding bases: Kyoto

#### China and Asia

- Lower demand for automotive
- Korea: Strong demands for home appliances

Sales offices: China and Korea Mold bases: China and Malaysia North America

- Robust demand for automotive
- Profit improvement progressed at Mexico factory due to strong demand for home appliance

Mexico factory: Operating profit expected to improve by 800 million JPY in FY2020

Sales offices: US

Molding bases: US and Mexico

Demands expand through our global network example:

Korea

Customer: Development Nissha: Sales and technical support

Mexico, US and China


Customer: Assembly

Nissha: Production of parts and modules



# Film-based touch sensor expand for Mobility (automotive)













#### Mobility (automotive) market needs for displays



Large screen ✓

Design flexibility and curved surface ✓

Optical properties ✓

Familiarity with OLED ✓

- Nissha film-based touch sensor meets the market needs
- Stable production capacity for mass volume
- Started mass production for mobility (automotive) in December 2019



## Growth of medical wearable sensors

2022

10

5

■ Left axis: Market size of connected medical devices

- Right axis: Nissha sales forecast of medical wearable sensors

(Billion JPY)

Market CAGR 16.2% 3,000 2,500

2,000 1,500

1,000

500

0

2018 2019

Based on our research out of several resources

2021

2020

Contract manufacturing

Develop wearable sensors utilizing the design and production capabilities for medical electrodes

Medical electrodes

ECG electrodes, etc.

Monitoring device for biological signal




\*Image is an illustration purpose

- Use: Heart disease (constant monitoring of arrhythmia, etc.)
- Data analysis in connection with IT equipment

Electrodes for cardiac mapping





- \*Image is an illustration purpose
- Use: Electrophysiological test

Monitoring devices (smart watch, etc.)



\*Image is an illustration purpose


### Market entry in DDS Acquisition of Zonnebodo Pharmaceutical completed



- Gain of business base for pharmaceuticals as business license, manufacturing facility, quality management system, sales channels, etc.
- Enhance of development for film type of pharmaceuticals
- Target for entry in Japanese market of film type of pharmaceuticals in 2024
- Aim for 20.0 billion JPY in sales of DDS by 2030

#### Our DDS Strategy

- Market opportunities in changing dosage forms from tablets and injections
- We do drug formulation design and manufacturing.
- Target on film type of pharmaceuticals
  - Transfer of Nissha's technologies to Zonnnebodo
  - Transfer of Nissha's technologies to a partner company in US






#### Securing of the leading position in metallized paper market by share extension Acquisition of Eurofoil Paper Coating in Germany completed






- Profitability improvement expected by leading the metallized paper market
- Enhance of R&D for new products by utilization of process engineering and production capabilities of Eurofoil
- Over net sales 22.0 billion JPY for metallized paper expected in 2020, risen from 15.6 billion JPY in 2019




More new products to markets seeking sustainable packaging materials, mainly for food market



# FY2020 Investment plan

- Total investment: 14.0 billion JPY
- M&A: 6.0 billion JPY, mainly in overseas
  - 3.0 billion JPY is for the deals made in FY2019
- Capital investment: 8.0 billion JPY for effective growth investment and renewal facilities
- Allocate gain on sales of strategically held shares (approx. 5.0) billion JPY)





## FY2020.12 Forecast

#### **EMPOWERING YOUR VISION**

(Millions of 1PY)

Reference

H1 include temporary expenses for Measures to Strengthen Profitability

Reflect the effect from H2

	(MIIIIONS OF JPY)						
		FY2019.12 (JanDec.) Result JGAAP	FY2020.12 (JanDec.) Forecast IFRS	FY2020.12 H1 (JanJun.) Forecast IFRS	FY2020.12 H2 (JulDec.) Forecast IFRS	FY2020.12 (JanDec.) Forecast JGAAP	$I \qquad Y \cap Y$
N	et sales	173,189	166,000	75,000	91,000	166,000	-4.2%
	Industrial Materials	46,463	53,000	25,500	27,500	53,000	+14.1%
	Devices	94,706	77,600	32,700	44,900	77,600	-18.1%
	Medical Technologies	24,068	25,700	12,400	13,300	25,700	+6.8%
	Information and Communication	7,417	7,800	3,600	4,200	7,800	+5.2%
	Others	534	1,900	800	1,100	1,900	+255.8%
0	perating profit	-4,307	-2,000	-6,000	4,000	-815	-
Op	erating profit margin	-2.5%	-1.2%	-8.0%	4.4%	-0.5%	+2.0pt
	Industrial Materials	-2,297	-300	-1,000	700	-222	_
	Devices	1,151	-200	-4,000	3,800	1,590	+38.1%
	Medical Technologies	174	1,600	750	850	718	+312.6%
	Information and Communication	-150	50	-50	100	59	Turn to black
	Others	-3,185	-3,150	-1,700	-1,450	-2,960	-
0	rdinary profit	-4,696	-	-	-	-1,515	-
Pr	ofit before tax	-	-2,700	-6,300	3,600	-	_
N	et profit	-4,131	-3,500	-6,900	3,400	-4,315	-
Fo	rex	¥108/\$	¥105/\$	¥105/\$	¥105/\$	¥105/9	\$

## FY2020.12 Forecast Conversion from JGAAP to IFRS

(Millions of JPY)

	FY2020.12 JGAAP	FY2020.12 IFRS	Difference	Adjustment
Net sales	166,000	166,000	0	
				Depreciation -833
Operating profit	-815	-2,000	-1,185	Amortization of goodwill +1,648
				*Extraordinary loss -2,000
Operating profit margin	-0.5%	-1.2%	-0.7pt	
Ordinary profit	-1,515	-		
Profit before tax	-	-2,700		
Net profit	-4,315	-3,500	+815	

\*Temporary expense for Measures to Strengthen Profitability



## Reference: Capital investment, Depreciation, M&A investment, Amortization of goodwill and R&D

(Millions of JPY)

	FY2019.12 Q1 (JanMar.) Results	FY2019.12 Q2 (AprJun.) Results	FY2019.12 Q3 (JulSep.) Results	FY2019.12 Q4 (OctDec.) Results
Capital investment	1,602	2,187	2,524	1,637
Depreciation	1,943	2,003	1,983	2,005
M&A investment	-	-	-	2,500
Amortization of goodwill	400	403	397	393
R&D	875	944	868	934



#### **EMPOWERING YOUR VISION**

This document contains confidential information and all rights regarding the document belong to Nissha Group. Therefore, any disclosure and/or leakage of the document to any third parties other than recipients of the documents, and copy, transfer and/or citation of the document without the prior authorization of Nissha Group are strictly prohibited. In addition, any use of the document for the purpose other than original purpose for the disclosure of the document is also prohibited.

本資料には機密情報が掲載され、一切の権利はNISSHAグループに帰属しているので、 NISSHAグループの事前の許可なく、本資料を受領者以外の第三者に開示、漏洩したり、 複写、転送、引用することを固く禁止いたします。また、本資料の開示目的以外での使 用は同様に禁止いたします。

